PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2019

The Aftermath of Surviving Acute Radiation Hematopoietic Syndrome and its Mitigation.

Mouse / Radiation

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 30730284 ↗2019Reported benefit

The Aftermath of Surviving Acute Radiation Hematopoietic Syndrome and its Mitigation.

MouseRadiationC3Hf/Sed//Kam and C57BL/6 (gnotobiotic, defined flora)Malen = 613 male C3H mice across 16 independent experiments and 61…Subcutaneous injection, with a minority of animals dosed orally1 to 75 mg/kg subcutaneously (doses of 1, 2, 5, 25, 50 and…First dose on day 1 after whole-body irradiation

Model: Single whole-body irradiation from a caesium-137 source at about 60 cGy/min, 7.725 Gy in C3H mice and 8.509 Gy in C57BL/6 mice, institutional LD70/30 estimates producing haematopoietic acute radiation syndrome

Active NPS/NPSP mitigators raised 30-day survival from 32.9% in diluent controls to 84.1% and extended median survival time during the acute syndrome from 17 to 18.5 days. Subacute mortality between 30 and 100 days was slightly higher in mitigated animals (about 10% versus one death in controls), b…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.